Ultra-resistant schizophrenia is not associated with the multidrug-resistant transporter 1 (MDR1) gene rs1045642 variant

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 236-238

  Mouaffak, Fayçal ^a,b,c   Kebir, Oussama ^a,c   Picard, Véronique ^d   Bonhomme Faivre, Laurence ^d   Millet, Bruno ^e   Olié, Jean Pierre ^a,b,c   Reynaud, Michel ^a,b,c   Krebs, Marie Odile ^a,b,c   Benyamina, Amine ^a,d,f  

^a CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CHLORPROMAZINE; CLOZAPINE; GLYCOPROTEIN P; HALOPERIDOL; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; REACTIVE OXYGEN METABOLITE; RISPERIDONE;

ADULT; BLOOD BRAIN BARRIER; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TRANSPORT; ENDOTHELIUM CELL; ETHNICITY; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; MULTIDRUG RESISTANCE; OXIDATIVE STRESS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; FEMALE; GENETIC VARIATION; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79952381379     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820f9152     Document Type: Letter

References (20)

1. Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 2001;27(4): 615-628. (Pubitemid 34093248)
2. Mouaffak F, Tranulis C, Gourevitch R, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol. 2006;29(1):28-33. (Pubitemid 44378609)
3. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004;10(12):1295-1312. (Pubitemid 38559749)
4. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525- 528. (Pubitemid 46175758)
5. Alenius M, Wadelius M, Dahl ML, et al. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res. 2008;42(11):884-893.
6. Lin YC, Ellingrod VL, Bishop JR, et al. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit. 2006;28(5):668-672. (Pubitemid 44564067)
7. Consoli G, Lastella M, Ciapparelli A, et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics. 2009;10(8): 1267-1276.
8. Jaquenoud Sirot E, Knezevic B, Morena GP, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29(4):319-326.
9. Benyamina A, Bonhomme-Faivre L, Picard V, et al. Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1270-1274.
10. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;(3): CD006324.
11. Takao T, Tachikawa H, Kawanishi Y, et al. Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene. Psychiatr Genet. 2006;16(2):47-48. (Pubitemid 44481201)
12. Yasui-Furukori N, Saito M, Nakagami T, et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(2):286-291. (Pubitemid 43288068)
13. Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics. 2006;7(7):987-993. (Pubitemid 44644778)
14. Bozina N, Kuzman MR, Medved V, et al. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res. 2008;42(2):89-97. (Pubitemid 350061252)
15. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem. 2004;4(13): 1385-1398. (Pubitemid 39242880)
16. Ziemann C, Burkle A, Kahl GF, et al. Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis. 1999;20(3):407-414. (Pubitemid 29112627)
17. Yu WY, Chang HW, Lin CH, et al. Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J Psychiatry Neurosci. 2008;33(3):244-247.
18. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia. 2010;51(8):1333-1347.
19. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71(2):163-169. (Pubitemid 34595435)
20. Bebawy M, Chetty M. Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. Bioessays. 2008;30(2):183-188. (Pubitemid 351196953)